| |
Dr. Susan Kahn renewed as Tier 1 Canada Research Chair in Venous Thromboembolism
 Venous thromboembolism (VTE), which refers to the
formation of blood clots in the veins, is an underdiagnosed and serious, yet
preventable cardiovascular disease that affects persons of all ages and
ethnicities. It is the third most common cardiovascular condition after heart
attack and stroke. Furthermore, up to 60 percent of VTE cases occur during
hospitalization or in the 6-week period post-discharge, making it a leading
cause of hospital-associated disability and even death in Canada. Lady Davis Institute
(LDI) Senior Investigator and McGill Professor of Medicine Susan Kahn has
devoted her career to reducing the incidence of VTE, enhancing its diagnosis
and therapeutic management, and improving patient safety and outcomes, both in
Canada and globally. On January 12, 2022, she was renewed as Tier 1 Canada
Research Chair in Venous Thromboembolism for another 7 years, in recognition of
the importance of her research for the health and well-being of all Canadians.
Dr. Kahn is a world expert in VTE. She
is the founder and director of the Centre of Excellence in Thrombosis and
Anticoagulation Care (CETAC) based at the Jewish General Hospital (JGH), one of
only three Royal College-approved training sites in thrombosis in Canada. Since
it opened in 2018, the CETAC has played a vital role in lessening
thrombosis-related mortality, morbidity and socioeconomic burden not only here
at the JGH but throughout the Quebec healthcare system.
Under her leadership, the JGH has been a
trailblazer in developing VTE prevention protocols and anticoagulation
guidelines at the national and international level. It has also built a unique,
multidisciplinary Thrombosis Program with patient care, training, education and
internationally recognized research components that are unparalleled in Quebec
and among the top programs in Canada.
Dr. Kahn is also co-Director of the
CIHR-funded Canadian Venous Thromboembolism Research Network (known as CanVECTOR),
a Canadian national venous thromboembolism research and training network.
“The renewal of this research chair will
be tremendously helpful in supporting my team’s ongoing research efforts to reduce
VTE occurrence, improve VTE diagnosis and therapeutic management, improve the
safety of anticoagulant delivery, and enhance the quality of life of those
impacted by VTE, both in Canada and globally,” says Dr. Kahn.
Other LDI researchers currently holding
Canada Research Chairs include:
- Shirin Abbasinejad Enger, Canada Research Chair in Medical Physics, CIHR, Tier 2
- Alexandre Orthwein, Canada
Research Chair in Genome Stability and Hematological Malignancies, CIHR, Tier 2
- Brett D. Thombs, Canada
Research Chair in Patient-engaged disease management and prevention, CIHR, Tier
1
“Canada Research Chairs recognize and
support outstanding researchers who are acknowledged by their peers as world
leaders or as having the potential to lead in their field. On behalf of the
entire LDI community, we congratulate Dr. Susan Kahn and all CRC holders for
their commitment and success at achieving excellence,” said Stephen Robbins,
Director of the LDI.
The Canada Research Chair program is a
tri-agency initiative of the Social Sciences and Humanities Research Council
(SSHRC), the Natural Sciences and Engineering Research Council (NSERC) and the
Canadian Institutes of Health Research (CIHR).
|